WATERTOWN, Mass.--(BUSINESS WIRE)--FORUM Pharmaceuticals Inc. (previously known as EnVivo Pharmaceuticals, Inc.), a biotechnology company singularly focused on the development and delivery of innovative medicines to treat challenging brain diseases, today announced the appointment of Todd Shegog as Senior Vice President and Chief Financial Officer. Mr. Shegog, former Senior Vice President, Finance and Chief Financial Officer at Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, brings to FORUM 20 years of financial experience in the biotechnology and pharmaceutical industries.<br /><br />    “FORUM faces a pivotal stage of development as it continues to mature into a late-stage biotechnology company, and I’m eager that I can contribute my financial experience in working with this dedicated team at this important inflection point in the company’s growth.”<br /><br />“Todd’s strong combination of leadership and financial experience in growing successful organizations should serve FORUM well as we continue building a fully sustainable company,” said Deborah Dunsire, M.D., President and Chief Executive Officer of FORUM Pharmaceuticals. “FORUM is poised to potentially commercialize the first innovative therapies for schizophrenia and Alzheimer’s disease in more than a decade, and we look forward to benefitting from Todd’s experience. We anticipate that his skills will be a valuable resource in the financial management of our ongoing worldwide Phase 3 clinical trials for encenicline in schizophrenia and Alzheimer’s disease and other active, earlier-stage investigational studies for diseases such as dementia.”<br /><br />Prior to FORUM, Mr. Shegog served as Senior Vice President, Finance and Chief Financial Officer at Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, where he was responsible for management of the company’s financial resources, corporate planning, financial reporting and compliance. During his tenure from 1998 to 2014, Mr. Shegog held key leadership roles supporting the early evolution of the company and its transformation from a genomics company to a fully-integrated drug developer, the approval and launch of its flagship oncology product, VELCADE®, and the $8.8 billion acquisition of Millennium by Takeda Pharmaceuticals. He began his career in healthcare at Genetics Institute (now Pfizer) in a variety of financial positions supporting its research and development organizations, and was a member of the Commercial Operations team that supported the launch of BeneFIX®. Mr. Shegog holds an M.B.A. from the Tepper School of Management, Carnegie Mellon University and a B.S. degree in electrical engineering from Lafayette College.<br /><br />“I’m excited to be part of this enthusiastic and dynamic company, which is so clearly driven in its mission to leverage compelling science into developing new medicines to treat brain disease,” said Mr. Shegog. “FORUM faces a pivotal stage of development as it continues to mature into a late-stage biotechnology company, and I’m eager that I can contribute my financial experience in working with this dedicated team at this important inflection point in the company’s growth.”<br /><br />About FORUM Pharmaceuticals Inc.<br /><br />FORUM Pharmaceuticals Inc. and its subsidiaries (“FORUM Pharmaceuticals” or “FORUM”) are dedicated to developing groundbreaking medicines in support of all those who are affected by or caring for people with serious brain disease, to help them live fuller, more enriching lives. The Company’s robust and diverse pipeline is focused on discovering and developing new treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provide improvement in cognitive and overall function. FORUM’s lead compound, encenicline hydrochloride (EVP-6124), is currently being evaluated in separate ongoing Phase 3 clinical trial programs: COGNITIV CIAS, which looks to improve cognitive impairment in patients with schizophrenia, and COGNITIV AD, which aims to improve cognition in patients with Alzheimer’s disease. Privately owned, FORUM Pharmaceuticals is based in Watertown, Mass. For more information about FORUM, visit www.forumpharma.com.